Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, DAX 40, Dow, Bitcoin,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Arkle,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Aminex,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, BSF,
Tirupati Graphite (TGR), the specialist graphite and graphene company, provided a progress update on three important workstreams.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Artemis, Boku, Audioboom,
Overall, AIM’s top shares enjoyed a good week. The junior market 100 indexes rose 0.5% in the past five days to 4,386. This was compared to a flat Footsie performance.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Bushveld, DeepVerge, Galileo,
Poolbeg Pharma (POLB), a clinical-stage infectious disease pharmaceutical company, said it has received ethics and competent authority approval to commence its Lipopolysaccharide human challenge clinical trial for POLB 001, which